Dr. Marc Cornier, MD
Claim this profileNovartis Investigative Site
Studies Cardiovascular Disease
Studies Feeding Disorders
3 reported clinical trials
5 drugs studied
Affiliated Hospitals
Clinical Trials Marc Cornier, MD is currently running
Energy Stimulus
for Feeding Disorders in Adolescents
The brain plays an integral role in how and what people eat. However, the brain's contribution to overeating is not well understood during sensitive developmental periods such as adolescence, when excessive weight gain and obesity prevalence are a significant concern.The proposed study will use functional magnetic resonance imaging to examine how the brain's response to excess energy is related to overeating in adolescents with and without obesity.
Recruiting0 awards N/A3 criteria
Combo Diabetes Drug
for Type 2 Diabetes
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will be followed for the occurrence of the trial primary endpoint of the total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, counting all events from randomization until end of study.
Recruiting3 awards Phase 48 criteria
More about Marc Cornier, MD
Clinical Trial Related4 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Marc Cornier, MD has experience with
- Pelacarsen (TQJ230)
- Energy Stimulus
- SGLT2 Inhibitor
- GLP-1 Receptor Agonist
- Combination Drug
Breakdown of trials Marc Cornier, MD has run
Cardiovascular Disease
Feeding Disorders
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marc Cornier, MD specialize in?
Marc Cornier, MD focuses on Cardiovascular Disease and Feeding Disorders. In particular, much of their work with Cardiovascular Disease has involved treating patients, or patients who are undergoing treatment.
Is Marc Cornier, MD currently recruiting for clinical trials?
Yes, Marc Cornier, MD is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Marc Cornier, MD has studied deeply?
Yes, Marc Cornier, MD has studied treatments such as Pelacarsen (TQJ230), Energy Stimulus, SGLT2 inhibitor.
What is the best way to schedule an appointment with Marc Cornier, MD?
Apply for one of the trials that Marc Cornier, MD is conducting.
What is the office address of Marc Cornier, MD?
The office of Marc Cornier, MD is located at: Novartis Investigative Site, Aurora, Colorado 80045 United States. This is the address for their practice at the Novartis Investigative Site.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.